PH12018502571A1 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer - Google Patents
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerInfo
- Publication number
- PH12018502571A1 PH12018502571A1 PH12018502571A PH12018502571A PH12018502571A1 PH 12018502571 A1 PH12018502571 A1 PH 12018502571A1 PH 12018502571 A PH12018502571 A PH 12018502571A PH 12018502571 A PH12018502571 A PH 12018502571A PH 12018502571 A1 PH12018502571 A1 PH 12018502571A1
- Authority
- PH
- Philippines
- Prior art keywords
- androgens
- prostate cancer
- treatment
- resistant prostate
- metastatic castrate
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Described herein are anti-androgens for use in treating non-metastatic castrate-resistant prostate cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/061197 WO2014052237A1 (en) | 2012-09-26 | 2013-09-23 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
US201661705900P | 2016-11-26 | 2016-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12018502571A1 true PH12018502571A1 (en) | 2020-12-07 |
Family
ID=74211847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12018502571A PH12018502571A1 (en) | 2013-09-23 | 2018-12-06 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH12018502571A1 (en) |
-
2018
- 2018-12-06 PH PH12018502571A patent/PH12018502571A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
SG11201510751YA (en) | Composition and vaccine for treating prostate cancer | |
TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
HK1217289A1 (en) | Compositions and methods for treatment of cancer using bacteria | |
EP3062808A4 (en) | Treatment of metastatic prostate cancer | |
EA201992251A1 (en) | ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION | |
IL242386B (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
MX2015006478A (en) | Glutamase inhibitors and method of use. | |
MX2015007185A (en) | Use of eribulin in the treatment of breast cancer. | |
MX2017006015A (en) | Apilimod for use in the treatment of renal cancer. | |
MX2017006026A (en) | Apilimod for use in the treatment of colorectal cancer. | |
MX2015013021A (en) | 5-bromo-indirubins. | |
PT3258931T (en) | Use of cabazitaxel in the treatment of prostate cancer | |
HK1215535A1 (en) | Cabazitaxel and its use for treating metastatic prostate cancers | |
PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
GB201612794D0 (en) | Therapeutic use of diethanololeamide in prostate cancer treatment | |
GB201322958D0 (en) | Uses of oligouronates in cancer treatment |